MyScent Diagnostics
Early Cancer Detection Using Urine or Breath
Company Overview
Snapshot
Founded in May 2013 by Ilan Alfia and Michal Mark Danieli, MyScent Diagnostics operates with 1–10 employees. The company is currently in the R&D product stage, focusing on developing its core technology for early cancer detection.
Business overview
MyScent Diagnostics is a Health Tech & Life Sciences company focused on developing solutions for the early detection of cancer. The company's core technology utilizes highly sensitive sensors to analyze volatile organic compounds in urine or breath samples, aiming to identify breast and lung cancer non-invasively. While primarily focused on cancer detection, the technology has broader applications across various diseases. MyScent Diagnostics operates within the medical devices and diagnostics devices sectors, targeting laboratories and healthcare providers within the healthcare and life sciences markets.
Log in to access full profile ›Company Intelligence Q&A
- What is MyScent Diagnostics' primary focus?
- MyScent Diagnostics is focused on the early detection of breast and lung cancer through non-invasive methods.
- What technology does MyScent Diagnostics utilize?
- MyScent Diagnostics uses highly sensitive sensors to test volatile organic compounds found in patient urine or breath samples.
- When was MyScent Diagnostics founded?
- MyScent Diagnostics was founded in May 2013.
- Who are the founders of MyScent Diagnostics?
- MyScent Diagnostics was founded by Ilan Alfia and Michal Mark Danieli.
- What is the current product stage of MyScent Diagnostics?
- MyScent Diagnostics is currently in the R&D product stage, developing its core technology for early cancer detection.